INTRODUCTION
The progression of cancer from microscopic dormant tumors into disseminated malignant disease is a highly complex process comprised of multiple sequential events. 1, 2 The existence of dormant tumors in otherwise healthy individuals is well documented. These quiescent lesions can be present as one of the earliest stages in tumor development, as well as a stage in tumor metastasis and residual disease following the treatment of primary tumors, 3 and can remain asymptomatic and hence, undetectable for years. 4 Nevertheless, the concern lies within the ability of microscopic lesions to 'escape' dormancy and evolve into malignant tumors. Numerous factors are associated with this process, including the ability of the tumor to induce the recruitment and formation of a functional vasculature. 5 The transition from a dormant nonvascular lesion to a highly vascular outgrowing malignant tumor is commonly referred to as the 'angiogenic switch'. 6, 7 This unique process, comprised of complex interactions between the tumor cells and other untransformed tumor-infiltrating cells, allows tumor growth beyond the size of B1 mm 3 . 5, 8 Various types of nontumor cells were shown to have role in tumor neovascularization, including endothelial progenitors, 9 fibroblasts 10 and several subpopulations of myeloid cells. [11] [12] [13] [14] Recently, CD11b þ Gr1 þ immature myeloid cells (IMCs) were reported to promote angiogenesis, and to have a key role in tumor progression. These cells are recruited from the bone marrow (BM), through the peripheral blood (PB) and into the tumor mass, in which they promote angiogenesis by locally secreting proangiogenic factors, such as matrix-metaloproteinases that in turn increase the bioavailability of vascular endothelial growth factor. [14] [15] [16] [17] [18] [19] Other studies demonstrated that IMCs mediate the refractoriness of tumors to antivascular endothelial growth factor therapy in mouse tumor models. 15, 20 Moreover, it was demonstrated that CD11b þ Gr1 þ IMCs promote also physiological angiogenesis in mouse models of hind limb ischemia and the development of the placental vasculature. 21, 22 Despite the increasing evidence of the importance of CD11b þ
Gr1
þ IMCs in tumor angiogenesis, the molecular mechanisms that govern their recruitment and function are largely unknown. Here, we studied a mouse intra-abdominal tumor model, in which dormancy versus expansive growth is dictated by the site of tumor implantation in the peritoneal cavity. 23, 24 Specifically, inoculation of tumor cells into the mouse peritoneal cavity led to differential growth, in which large, vascular tumors formed in the upper region of the peritoneal cavity and small, nonvascular tumors formed on the mesentery in the lower abdomen. This allowed us to investigate the recruitment and function of CD11b þ Gr1 IMCs along their recruitment enabled us to identify key genes that may contribute to their role in tumor angiogenesis.
RESULTS

CD11b
þ Gr1 þ IMCs are preferentially recruited into vascular versus dormant tumors We initially examined whether there is a differential recruitment of IMCs into vascular versus dormant tumors. To this end we injected Lewis Lung Carcinoma cells into the mouse peritoneal cavity of C57Bl/6J mice. This led to the formation of a large tumor in the upper region of the peritoneal cavity, and several small tumor implants on the mesentery in the lower abdomen of the same mouse ( Figure 1a) . 23, 24 Significantly, 7 days following inoculation, the upper abdominal tumor mass was more than 40-fold larger than that of lower abdominal tumors (Figure 1a ). When compared with lower tumors, upper abdominal tumors were highly angiogenic as determined by gross appearance and by the histological sections, demonstrating increased numbers of platelet endothelial cell adhesion molecule 1 (PECAM1/CD31) expressing endothelial cells within a similar population of malignant tumor cells (Figure 1b) . Importantly, the vascular tumors showed a B2.5-fold increased population of CD11b þ Gr1 þ IMCs when compared with dormant tumors (Figures 2a and b) . These cells, also detected as SSC high (not shown) reflecting their granulocytic nature, comprised B25% of the CD45 þ cells populating the vascular tumors. We next analyzed the effect of tumor presence on IMC populations in the different compartments. When compared with tumor free mice, mice harboring Lewis Lung Carcinoma cell tumors presented a marked increase in CD11b þ Gr1 þ IMCs in the PB and in the spleen (Figure 2c) . Importantly, the level of IMCs within the BM was not affected by the tumor presence (Figure 2c ).
Global gene expression of CD11b
þ Gr1 þ IMCs in different blood compartments and tumor tissue IMCs are recruited from the BM, through the PB into the tumor mass. 19 In order to characterize the molecular events that coincide with the differential recruitment of these cells into vascular versus (Figures 3a and b) . The expression level of 1538 genes changed by more than twofold between the PB and BM, of which 615 were upregulated and 923 were downregulated (Figure 3c ). Importantly, pronounced transcriptional changes were demonstrated when the expression pattern in the upper and lower Genes are plotted according to their expression levels in the different tissues. Dots represent genes that are differentially expressed by more than twofold between tissues. Increasing gene density of genes that are not differentially expressed, is marked by color intensity. Three biological repeats were performed in each condition (BM, PB, lower and upper tumors). At least 1.5 Â 10 5 cells were collected by cell sorting in each repeat.
Immature myeloid cells in tumor dormancy N Pencovich et al and prominent role in angiogenesis were overexpressed in upper vascular relative to lower dormant tumors. These genes include: Adm, Dmbt1, Mmp12, Fn1, Ppbp, Cyr61, Vcan, Arg1, Klk1, Spp1, Serpine1, Dkk2, Hyal1, Myc, Plxna4, Cav1 and others ( Figure 5 and Supplementary Table S1 ). In order to validate the microarray expression data, we performed real-time quantitative PCR for selected genes (Figure 4d ). These genes were shown to take part in tumor progression, and specifically tumor angiogenesis through inflicting changes in the extracellular matrix, increasing vascular endothelial growth factor bioavailability, promoting blood vessel formation, activating and recruiting IMCs, and others. own blood supply and growth. Although originating from normal cells within the body, tumors act somewhat like foreign parasites and exploit the host reservoirs, while using biological processes designed to serve normal developmental processes. Angiogenesis is a pivotal biological process required in the developing embryo and in selected conditions in the adult, such as wound healing, coping with tissue ischemia and pregnancy. Harnessing this physiological process by tumors is a rate-limiting step for the 'angiogenic switch', that is, tumor transition from a dormant nonvascular lesion to a highly vascular malignant tumor. [5] [6] [7] [8] Complex tumor À host interactions are required for this tumor vascularization, including the infiltration of nonmalignant stromal cells into the tumor mass. Of these, several lines of evidence point at CD11b
þ Gr1 þ IMCs, that are recruited from the BM via PB into the tumor, as key players in this process. [14] [15] [16] [17] [18] [19] [20] Gaining insight into the molecular events paralleling the recruitment of these cells into tumors that have or have not undergone the 'angiogenic switch' was the primary goal of this study.
We used a mouse model, in which a single intra-abdominal inoculation of tumor cells leads to the formation of both dormant and angiogenic tumors at the same time. 23, 24 Specifically, a large angiogenic tumor developed in the upper abdominal cavity, while small dormant tumors occupied the mesentery in lower abdomen. The mechanism for this site directed tumor dormancy is not completely understood although it has been linked to differential thrombospondin activity. 24 Nevertheless, it is a useful model to study the differential development of angiogenic versus dormant tumors. We first demonstrated a significant enrichment of CD11b þ Gr1 þ IMCs within upper vascular tumors as compared with lower tumors, correlating with a prominent increase in tumor angiogenesis. Because CD11b þ Gr1 þ IMCs populations were highly enriched within the PB and spleens of tumor bearing mice as compared with mice without tumors, it is conceivable that IMCs that originate from the BM are recruited by the tumors via the PB. Although significant, the observed increased percentage of CD11b þ Gr1 þ IMCs by itself (about 2.5-fold) in the upper vascular versus lower dormant tumors, cannot fully explain the marked difference in vascularization between these simultaneously growing tumors. Hence, we postulated that there might be intrinsic differences between IMCs populating the upper versus lower tumors. Variations at the molecular level might affect not only the ability of IMCs to functionally promote angiogenesis, but also their ability to produce factors important for further IMC recruitment. Therefore, we set off to explore the global expression pattern of CD11b þ Gr1 þ IMCs throughout their route of migration from the BM through the PB and into upper versus lower tumors.
We observed that the genome wide expression pattern of CD11b þ Gr1 þ IMCs is markedly different along their migration though the different compartments. Egression of IMCs from BM into the PB was associated with an extensive transcriptional response. This significant gene expression alteration is most probably needed for the cells to properly respond to various recruitment stimuli, emerge from the BM, and adapt to PB environment. Additionally, it is possible that this expression pattern also reflects homing processes of the cells into the tumors. As our goal was to evaluate the differences in recruitment of IMCs between dormant and angiogenic tumors, we focused on transcriptional changes between upper/lower tumors and PB. Upon migration of CD11b þ Gr1 þ IMCs from the PB into lower dormant tumors, a relatively small number of genes were differentially expressed. However, recruitment of IMCs into upper vascular tumors was associated with a profound transcriptional response, in which more than 1800 genes were differentially expressed by at least twofold compared with PB. Importantly, B72% of the differentially expressed genes in lower tumors compared with PB were overexpressed also in the upper tumors (314 out of 436). Nevertheless, an additional set of 1438 genes, more than three times the total number of genes differentially expressed in the lower tumors, were differentially expressed by at least twofold compared with PB only in the upper tumors. This striking difference suggests that the upper vascular tumors are able to inflict a greater effect on the biology of IMCs than the respective lower dormant tumors. These enhanced tumor À IMC interactions correlate both with the increased numbers of IMCs within the tumor and possibly also with an improved functional capacity of these cells that lead to increased tumor angiogenesis. We therefore, speculate that the minute gene expression changes observed in the lower dormant tumors, that was shared by the upper vascular tumors, is merely the result of an environment change, and is not sufficient to induce the angiogenic properties of these cells. This notion is further supported by the decreased vascularization and the dormant nature of these tumors. Of note, another possibilty that cannot be completely ruled out, is that the observed changes in global gene expression between IMCs derived from upper vascular versus lower dormant tumors, may reflect differential recruitment of slightly different subsets of this heterogeneous population IMCs. In order to pinpoint the most profound changes in gene expression between IMCs derived from the different tumors, we closely evaluated the specific genes that were differentially expressed by at least twofold between the upper vascular and lower dormant tumors. Importantly, a large set of genes that were shown to have key roles in angiogenesis were significantly upregulated in the upper tumor compared with lower tumor IMCs. Adm, Dmbt1 and Vcan genes, upregulated by more than threefold in upper versus lower tumors, were shown to be secreted into the tumor extracellular matrix and to promote angiogenesis by different mechanisms. 25, 26, 31 Moreover, Adm was previously shown to be secreted specifically by tumor-infiltrated macrophages and promote angiogenesis a paracrine and autocrine manner. 25, 26 Cyr61 gene, upregulated by more than fourfold in the upper tumors, was also associated with increased tumor vascularity and metastasis. 37 Other genes also associated with angiogenesis, including Arg1, Klk1, Serpine1, Dkk2, Hyal1, Myc, Plxna4, Cav1 and others were also significantly upregulated in upper versus lower tumors derived IMCs. [33] [34] [35] [38] [39] [40] [41] [42] Notably, only a few genes associated with angiogenesis were overexpressed in the lower dormant tumor derived IMCs including Cd74, Lifr, IL23a. [43] [44] [45] Intriguingly, a large set of genes, overexpressed in the upper vascular tumors included genes known to be of pancreatic origin. These include enzymes such as Amy2a5, Amy2b, Ctrb1, Clps, Cpa1, Zg16, Sycn, Reg1 and others ( Figure 5 and data deposited online). Importantly, some of these genes were reported also to be involved in angiogenesis and tumor progression, 46, 47 however, a direct mechanism for these extra-pancreatic activities has not been established. One possibility is that these enzymes that include proteases, lipases and amylases may take part in matrix remodeling thereby enabling the intrusion and formation of intratumor blood vessels.
In order to address the functional proangiogenic properties of tumor derived IMCs in vivo we used Matrigel plug assays. Because of technical limitations, namely the lack of sufficient numbers of IMCs that could be isolated from dormant tumors, we could only test IMCs derived from expansive proangiogenic tumors. We compared the ability of IMCs to recruit endothelial cells into Matrigel plugs, to that of control-non IMC-BM derived cells 21 In conclusion, we suggest a model, in which proangiogenic versus nonangiogenic transcriptional patterns is associated with the ability of IMCs to promote tumor angiogenesis. The difference between these two transcriptional programs lies in reaching a threshold of proangiogenic genes that need to be activated in order to 'tip the balance' and enable IMCs to promote tumor angiogenesis and growth. In the IMCs extracted from dormant tumors, this 'tipping point' is not achieved resulting in a nonangiogenic phenotype. Although the mechanism governing these differential tumor À IMC interactions remains unclear, this study provides insight into what seems as a broad, yet unknown, field of research in the pursuit to understand cancer progression.
MATERIALS AND METHODS
Experimental system
Lewis Lung Carcinoma cells (purchased from ATCC, Manassas, VA, USA), were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (Invitrogen Life Technologies, Burlington, Ontario, Canada), 2 mM L-glutamine and penicillin/streptomycin (Biological industries, Kibbutz beit haemek, Israel) at 37 1C and 5% CO 2 . For in-vivo experiments, 1 Â 10 6 Lewis Lung Carcinoma cells cells were harvested from subconfluent cultures using Trypsin-EDTA, solution B (Biological industries, Kibbutz beit haemek, Israel), washed, resuspended in 100 ml of phosphate-buffered saline (PBS) and injected intraperitonealy to 8-week-old, male, C57Bl/6J mice (purchased from Harlan Laboratories, Ein Kerem, Israel). The mice were euthanized and the tumors extracted and analyzed 7/10 days following the injections. All animal procedures were performed in compliance with Weizmann Institute of Science guidelines and protocols approved by the Institutional Animal Care and Use Committee.
Flow cytometry
Tumors specimens were incubated in Dulbecco's PBSwith calcium chloride and magnesium chloride supplemented by 1 mg/ml collagenase type-IV (Sigma-Aldrich, Rehovot, Israel) and 0.2 mg/ml DNase I (Roche Diagnostics, Mannheim, Germany) at 37 1C for 1 h. Digested tissue were then filtered through a 100 mM cell strainer and resuspended in fluorescence-activated cell sorting (FACS) buffer (PBS, 5 mM EDTA, and 3% fetal bovine serum). Immunostaining was performed in the presence of rat antimouse Fc receptor III/II (FcgammaRIII/II) (CD16/32; eBioscience, San Diego, CA, USA), by incubating the cells with monoclonal antibodies for 30 min on ice. Staining reagents included fluorescein isothiocyanate conjugated anti-Ly-6G (Gr1) and Ly6C (RB6-8C5), and allophycocyanin) conjugated anti-CD45, were purchased from BD Biosciences (San Jose, CA, USA). Phycoerythrin conjugated anti-CD11b was purchased from eBioscience. Flow cytometry was performed with a FACSSort (Becton Dickinson, Mountain View, CA, USA). The data was analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Immuno-histochemistry
Frozen sections (10 mm) of tumor tissues were fixed with acetone ( À 20 1C), washed in PBS, and blocked with 20% horse serum in PBS. After immunostaining with phycoerythrin conjugated antiPECAM1 (eBioscience), mounting was performed on glass slides with ProLong Gold antifade reagent with 4 0 -6-diamidino-2-phenylindole Mounting Media (Invitrogen Life Technoloies, Burlington, Ontario, Canada). Optical sections were scanned using a Zeiss LSM 510 Meta Duoscan confocal system (Carl Zeiss, Jena, Germany).
Microarray processing and analysis RNA from at least 1.5 Â 10 5 cells, collected by cell sorting in each biological repeat, was extracted by EZ-RNA (Biological Industries, Beit Haemek, Israel), according to manufacturer instructions. Purified RNA was reversetranscribed, amplified and labeled with Affymetrix GeneChip whole transcript sense target labeling kit (Affymetrix, Santa Clara, CA, USA).
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Labeled cDNAs were analyzed using Affymetrix mouse gene ST 1.0 microarrays, according to manufacturer instructions. Microarrays were scanned using GeneChip scanner 3000 7G. Probe-set annotations were downloaded from the manufacturer's website (http://www.affymetrix.com/browse/products.jsp?navMode=34000 &productId=131476&navAction=jump&aId=productsNav#1_3). Microarray data was normalized with the Robust Multi-Array Average model (Bioconductor/affy package v1.32.1). Differentially expressed genes were called by applying analysis of variance on the probe-expression followed by false-discovery rate multiple-testing correction requiring q-value equal or smaller than 0.1, and/or changes in mean expression of at least twofold between conditions. Gene expression was clustered and visualized with custom R-scripts using the base and gplot2 packages (R version, 2.14.1; http://cran.r-project.org/bin/windows/base/old/2.14.1/).
Real-time PCR
Quantitative PCRs were performed using light cycler 480 (Roche Applied Science, Indianapolis, IN, USA) with 480 SYBR Green I Master (Roche). PCR primers are listed in Supplementary Table S2 .
Statistical analysis
All the data presented in histograms are expressed as mean±s.d. or s.e. Statistical significance was analyzed using paired 2-tabled Student's t-test.
